Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 7% of patients surviving past 5 years. T-cell immunity has been linked to the exceptional outcome of the few long-term survivors, yet the relevant antigens remain unknown. Here we use genetic, immunohistochemical and transcriptional immunoprofiling, computational biophysics, and functional assays to identify T-cell antigens in long-term survivors of pancreatic cancer. Using whole-exome sequencing and in silico neoantigen prediction, we found that tumours with both the highest neoantigen number and the most abundant CD8+ T-cell infiltrates, but neither alone, stratified patients with the longest survival. Investigating the specific neoantigen qualities promoting T-cell activation in long-term survivors, we discovered that these individuals were enriched in neoantigen qualities defined by a fitness model, and neoantigens in the tumour antigen MUC16 (also known as CA125). A neoantigen quality fitness model conferring greater immunogenicity to neoantigens with differential presentation and homology to infectious disease-derived peptides identified long-term survivors in two independent datasets, whereas a neoantigen quantity model ascribing greater immunogenicity to increasing neoantigen number alone did not. We detected intratumoural and lasting circulating T-cell reactivity to both high-quality and MUC16 neoantigens in long-term survivors of pancreatic cancer, including clones with specificity to both high-quality neoantigens and predicted cross-reactive microbial epitopes, consistent with neoantigen molecular mimicry. Notably, we observed selective loss of high-quality and MUC16 neoantigenic clones on metastatic progression, suggesting neoantigen immunoediting. Our results identify neoantigens with unique qualities as T-cell targets in pancreatic ductal adenocarcinoma. More broadly, we identify neoantigen quality as a biomarker for immunogenic tumours that may guide the application of immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In rare patients with localized PDAC who are long-term survivors, bacteria can translocate from the intestine into the tumour and control anti-tumour immune activation11,12.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [12]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, the gut microbiota can indirectly increase the immunogenicity of tumor cells by providing tumor cross-antigens to promote the efficacy of ICI [50, 68, 69].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PDAC tumors from long term survivors have high quantity and quality of neoantigens, and stronger infiltration and activation of CD8+ T cells”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These data suggest that microbial host factors, independent of the genomic composition of the tumor, may determine tumor behavior and patient outcomes.”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Significantly, the aggressive progression of PDAC, characterized by immune evasion and therapeutic resistance, is heavily influenced by the TME (Balachandran et al., 2017).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationWhole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki-Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 849
Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 829
Cited by
Items 901–1,000 of 1,001
The underexplored complexity of pancreatic cancer: Early dissemination and quiescence
Kumar, N. K., Kaur, A. B., Batra, S. K., & Ponnusamy, M. P. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189606 · Cited by 2
Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond
Schürmann, H., Park, W., O'Kane, G. M., Sciortino, C., Niger, M., Reichert, M., Olive, K. P., Pretzell, I., & Westphalen, C. B. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01236-x · Cited by 3
Amburn, T., Davenport, D. L., Patel, R. A., Moss, J. J., Pandalai, P. K., Kim, J., & Cavnar, M. J. (2022) · The American Surgeon · doi:10.1177/00031348221117031 · Cited by 2
A pharmacological strategy to recapitulate exercise-induced antitumoral immunity
Rébillard, A., Nunès, J. A., & Carrier, A. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.08.004 · Cited by 2
Zhou, J., Jian, F., Li, B., Sun, J., & Wang, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23004 · Cited by 2
The mechanism of USP43 in the development of tumor: a literature review
Zhao, Z., Liu, M., Lin, Z., Zhu, M., Lv, L., Zhu, X., Fan, R., Al-Danakh, A., He, H., & Tan, G. (2024) · Aging · doi:10.18632/aging.205731 · Cited by 4
Yablonski, J., Shi, C., & Chen, W. (2025) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqae184 · Cited by 2
Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
Demir, T., Moloney, C., & Mahalingam, D. (2025) · Cancers · doi:10.3390/cancers17050715 · Cited by 4
Tumor-specific CXCR6 positive precursor CD8+ T cells mediate tumor control in metastatic melanoma
Song, Y., Chen, J., Zhang, Y., Wu, N., Zhu, Y., Chen, G., Miao, F., Chen, Z., & Wang, Y. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01040-1 · Cited by 3
Personalized neoantigen-based cancer immunotherapy. A literature review
Aguirre, J. P. O., Vargas, E. A. V., Bohórquez, O. M. R., Amaya-Ramírez, D., Bernal-Estévez, D. A., & Parra-López, C. (2021) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v69n3.81633 · Cited by 2
Голота, А. С. (2021) · Physical and rehabilitation medicine medical rehabilitation · doi:10.36425/rehab79387 · Cited by 2
Panni, U. Y., Chen, M. Y., Zhang, F., Cullinan, D. R., Li, L., James, C. A., Zhang, X., Rogers, S., Alarcon, A., Baer, J. M., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03463-x · Cited by 2
Du, Q., Zhan, Y., Zhang, Z., Yang, J., Jonckheere, N., Shi, S., Wang, W., Xu, J., Liu, J., & Yu, X. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-24-340 · Cited by 4
Chiang, C. L.-L., & Kandalaft, L. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823901-8.00001-7 · Cited by 3
[MUC16: The Novel Target for Tumor Therapy].
Gao, R., Lou, N., Han, X., & Shi, Y. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.101.31 · Cited by 4
The Microbiome in Gastrointestinal Cancers
White, M. G., & Wargo, J. A. (2022) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2022.06.007 · Cited by 2
Comprehensive immunoprofile analysis of prognostic markers in pancreaticobiliary tract cancers
Kim, J. E., Kim, H. M., Kim, B., Chung, H. G., Chung, H. H., Kim, K. M., Kim, S. H., Jeong, W. K., Kim, Y. K., Min, J. H., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5530 · Cited by 2
Advances in Natural Killer Cells and Immunotherapy for Gastric Cancer
Ma, S., Li, L., Yin, J., Wang, X., Yang, C., Zhang, L., Guo, T., & Cai, H. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109695 · Cited by 2
Hu, H., Xu, Y., Zhang, Q., Ai, X., Wang, T., Li, H., Jin, C., Ouyang, C., & Wu, Z. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05824-0 · Cited by 3
Putting a number on neoepitope quality
Jarchum, I. (2018) · Nature Biotechnology · doi:10.1038/nbt.4074 · Cited by 2
Immunotherapy in Pancreatic Cancer
El‐Rayes, B. F., & Akce, M. (2020) · Digestive Disease Interventions · doi:10.1055/s-0040-1718904 · Cited by 2
Immuno-Oncology in Pancreatic Cancer
Jamieson, N. B., & Steele, C. W. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_20 · Cited by 2
Preface: More than two decades of modern tumor immunology
Galluzzi, L., & Rudqvist, N.-P. (2020) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(20)30020-3 · Cited by 2
Bednar, F., Olsen, L., & di Magliano, M. P. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-2732 · Cited by 3
Su, M., Qin, H., Shen, J., An, H., & Cao, Y. (2025) · Journal of Cell Communication and Signaling · doi:10.1002/ccs3.70033 · Cited by 3
Immunotherapy for Pancreatic Cancer
Sunami, Y., Rieder, S., Michl, P., & Kleeff, J. H. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_223 · Cited by 1
Targeting intratumoral heterogeneity in pancreatic cancer with sequential TIL infusions
Arruda, L. C. M., Karbach, J., Kiselicki, D., Sinelnikov, E., Gustavus, D., Hoffmeister, H., Atmaca, A., & Jäger, E. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102141 · Cited by 1
TLR2 signaling regulates T cell exclusion in pancreatic ductal adenocarcinoma.
Plesset, J. B., Stone, M. L., McVey, J. C., Coho, H., Markowitz, K., Coho, K. S., Lee, J., Thickens, A. S., Delman, D., & Beatty, G. L. (2026) · JCI Insight · doi:10.1172/jci.insight.195329 · Cited by 1
The role of gut microbiota in obesity-related cancers
Shi, W., Song, B., Xia, S., & Jia, D. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.04.002 · Cited by 1
MANFOUO, W. Q. W., & 华晔 (2026) · Discover Oncology · doi:10.1007/s12672-026-05030-z · Cited by 1
Saha, S., Chakraborty, S., & Nayak, A. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105345 · Cited by 1
Kim, B., & Lee, J. H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135682 · Cited by 2
Pancreatic Cancer: Translating Tumor Biology into Actionability
Balogun, F. O., Sherman, M. H., Park, W., Soares, K. C., Reyngold, M., Schoenfeld, J. D., Singhal, A., Iacobuzio–Donahue, C. A., & O'Reilly, E. M. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-2014 · Cited by 3
Self-citationRusciano, D. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1897032 · Cited by 1
MSH6 germline mutations leading to Lynch syndrome-associated cholangiocarcinoma: a case report
Zhang, Z., Ma, S., Li, S., Chen, Z., Song, R., & Wang, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1414665 · Cited by 1
Comprehensive analysis of UPK3B as a marker for prognosis and immunity in pancreatic adenocarcinoma
Jian, Z., Pan, T., Li, R., Zhang, W., Cheng, T., Zhang, H., Song, J., Shi, N., & Zhang, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-97213-x · Cited by 1
mRNA technology helps reinvigorate the hunt for cancer vaccines
Nogrady, B. (2025) · Nature · doi:10.1038/d41586-025-01151-7 · Cited by 1
Vaccines as Prophylactics and Therapeutics
Bagwe, P., Vijayanand, S., & Gaur, A. (2025) · Springer eBooks · doi:10.1007/978-3-031-81787-8_2 · Cited by 3
Tsai, A. K., Rollins, M. R., Ellefson, M. A., Schmiechen, Z. C., Burrack, A. L., Hulbert, A., Qian, G., Zhang, H., Cruz-Hinojoza, E., Butler, J. Z., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1101/2025.06.04.657887 · Cited by 1
Lin, L., Norrsell, R., Andersson, R. E., Shen, X., & Ansari, D. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102280 · Cited by 2
Gajda, M., Grudzińska, E., Liszka, Ł., Pilch-Kowalczyk, J., & Mrowiec, S. (2025) · Life · doi:10.3390/life15121833 · Cited by 1
Yuntao, Y. A. N. G., Zhang, Y., Shen, Z., Chen, S., Zhang, Y., & Wang, X. (2026) · Open Medicine · doi:10.1515/med-2025-1323 · Cited by 1
Cabral, F. V., Quílez-Alburquerque, J., Mooradian, O., Vytheswaran, S., Parshad, B., Obaid, G., Huang, H., & Hasan, T. G. (2026) · Advanced Science · doi:10.1002/advs.75291 · Cited by 1
Taing, K., Dabirian, K., & Shreenivas, A. V. (2026) · Cancers · doi:10.3390/cancers18091420 · Cited by 1
Peptides as integrative modulators for clinical prognosis and targeted therapy in pancreatic cancer
Yadav, B., Kollur, S. P., Ali, A., Arora, P., Gupta, A., Saranraj, P., Upadhye, V. J., & Singh, P. (2026) · Discover Oncology · doi:10.1007/s12672-026-05130-w · Cited by 1
Antignani, G., Feodoroff, M., Chiaro, J., Feola, S., Russo, S., Hamdan, F., Fusciello, M., D’Alessio, F., Bottega, P., Giannoula, Y., et al. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201247 · Cited by 2
Wang, B.-R., Yelleswarapu, M., Descamps, L., & Eduati, F. (2026) · Molecular Systems Biology · doi:10.1038/s44320-026-00221-w · Cited by 1
PARP7 inhibitors enhance the immunogenic effects of radiation in pancreatic cancer cells
Bragato, N., Dias, A. B., Ohradanova‐Repic, A., Dupanovic, A., Horvat, F., Fischer, P., Appel, L.-M., Walch, L., Kleinwächter, A., Rohrer, A. M., et al. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201258 · Cited by 1
KRAS-driven cytokine–metabolic crosstalk shapes immune exclusion in pancreatic ductal adenocarcinoma
Huang, C., Mai, G., Li, Y., Liu, H., & Huang, W. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1899014 · Cited by 1
Demircan, T., Yıldırım, B., Ünsal, H. İ., & Bılır, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188163 · Cited by 1
Li, Q., Hoffman, M. T., Chun, J.-H., Parent, B. D., Hambitzer, F., Peprah, F., Kureshi, C. T. S., Lim, B. S., Chang, E., Walsh, M. J., et al. (2026) · Cell · doi:10.1016/j.cell.2026.08.045 · Cited by 1
Krieger, E., & Toor, A. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00777 · Cited by 2
Cleaved CDCP1 marks the spot: a neoepitope for RAS-driven cancers
Donahue, K. L., & di Magliano, M. P. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157168 · Cited by 2
Precision Approaches to Pancreatic Cancer Therapy: What Now and What Next?
Keane, F., Park, W., & O'Reilly, E. M. (2022) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-022-00386-x · Cited by 2
Direct identification of T cell epitopes in cancer tissues
Shao, Y., Zhang, T., Celiker, B., & Fujiwara, K. (2023) · Annals of Pancreatic Cancer · doi:10.21037/apc-2023-1 · Cited by 1
Probiotics-based Anticancer Immunity in Breast Cancer
Masood, N., & Malik, S. S. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815124781123030009 · Cited by 1
Prognostic Impact of Phenotypic and Genetic Features of Pancreatic Malignancies
Potievskiy, M. B., Nekrasova, L. A., Korobov, I. V., Bykova, E. A., Moshurov, R. I., Sokolov, P. V., Shatalov, P. A., Falaleeva, N. A., Petrov, L. O., Trifanov, V. S., et al. (2025) · Life · doi:10.3390/life15040635 · Cited by 1
Raf kinase inhibitor protein modulator of gut microbiota and immunotherapy responses in cancer
Palma, G., Bruzzese, F., Meo, C., & de Nigris, F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189364 · Cited by 3
Relying on quality over quantity
Romero, D. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.189 · Cited by 1
PD-1/PD-L1 Blockade: A New Promising Therapy for the Treatment of Pancreatic Cancer?
Gagliano, N., & Sommariva, M. (2018) · Pancreas - Open Journal · doi:10.17140/poj-2-e007 · Cited by 1
Rationale for Immunotherapy in Gastrointestinal Malignancies
Michalarea, V., & Smyth, E. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00020-x · Cited by 1
The double-edged sword of cancer mutations: exploiting neoepitopes for the fight against cancer
Alvarado-Cruz, I., Meas, R., Paluri, S. L. A., Carufe, K. E. W., Khan, M., & Sweasy, J. B. (2019) · Mutagenesis · doi:10.1093/mutage/gez049 · Cited by 1
Rewiring local immune milieu by boosting dendritic cell for pancreatic cancer treatment
Zhang, Y., & Lei, Q. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00225-4 · Cited by 1
The microbiota is a potential mediator of the crosstalk between γδ T cells and tumors
Wang, H., Li, J., He, Y., & Yin, J. (2022) · Exploration of Immunology · doi:10.37349/ei.2022.00036 · Cited by 1
Pancreas cancer, careful improvements and human connections
Lloyd, S. A. J. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.09.20 · Cited by 1
Delfino, P., Neander, C., Filippini, D., D’Agosto, S. L., Vicentini, C., Fiorini, E., Lupo, F., Fiorini, C., Rusev, B. C., Tane, G. D. T., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/759779 · Cited by 1
Separating the Local and Malignant Dimensions of Cancer Adaptation
Roche, B., & Martinez, P. (2019) · Cancer Informatics · doi:10.1177/1176935119872954 · Cited by 1
Riedel, E., Hildebrandt, G., & Zipp, H. (1979) · PubMed · Cited by 2
Riesgo-Ferreiro, P., Gudimella, R., Bukur, T., Sorn, P., Rösler, T., Schrörs, B., & Löwer, M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.31.478157 · Cited by 1
Preface: More than two decades of modern tumor immunology
Galluzzi, L., & Rudqvist, N.-P. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(19)30459-8 · Cited by 1
Berzofsky, J. A., Howe, S. B., & Olkhanud, P. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00211-1 · Cited by 4
Preface: More than two decades of modern tumor immunology
Galluzzi, L., & Rudqvist, N.-P. (2020) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(20)30043-4 · Cited by 1
Lees‐Miller, S. P. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732976037.793546302 · Cited by 2
Pearce, H., Croft, W. D., Nicol, S. M., Margielewska‐Davies, S., Powell, R., Cornall, R. J., Davis, S. J., Marcon, F., Pugh, M., Fennell, É., et al. (2023) · doi:10.1158/2326-6066.c.6534790 · Cited by 1
Coley, A. K., Nawrocki, C., Patel, B. K., Pankaj, A., Guo, Z., Emmett, M. J., Lang, E. R., Song, Y., Xu, K. H., Ferrone, C. R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.04.570014 · Cited by 3
Targeting Neoantigens Conserved Across Organs and Species Overcomes Tumor Immune EscapePreprint
Mestrallet, G., Ward, R. W., Brown, M., Boumelha, J., Rentzeperis, F., Vaninov, N., Saffern, M., Olumuyide, E., Suri, P., Balan, S., et al. (2025) · SSRN Electronic Journal · doi:10.1101/2025.09.25.678519 · Cited by 1
Neue Ansätze in der Therapie des metastasierten Pankreaskarzinoms
Westphalen, C. B., & Heinemann, V. (2018) · Im Focus Onkologie · doi:10.1007/s15015-018-4103-y
Prediction of neoantigens and their application in cancer treatment
Jin, B., Wang, Y., & Du, S. (2018) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2018.07.010
Defining Neoepitopes that Contribute to Tumor Immunity
Brennick, C. A. (2018) · OpenCommons at University of Connecticut (University of Connecticut)
Sivaram, N., McLaughlin, P. A., Han, H. V., Petrenko, O., Jiang, Y.-P., Ballou, L. M., Pham, K., Liu, C., van der Velden, A. W. M., & Lin, R. Z. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/521831
Exosomes from Pancreatic Juice: A Step Closer to the Holy Grail?
Lowy, A. M. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07271-5
Application of neoantigens in malignant tumor treatment and prognosis evaluation
Chen, Q., Li, J., & Du, S. (2019) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v27.i5.287
Rethinking T Cells in Pancreas Cancer
Medina, B. D., & Miller, G. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1073
Self-citationRegional Gene Therapy for Cancer
Cherkassky, L., Grosser, R. A., & Adusumilli, P. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-28891-4_5
Molecular and morphologic study of pancreatic cancer evolution
Noë, M. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/3
Targeting the Immune System in Pancreatic Cancer
Kabacaoğlu, D., Ruess, D. A., & Algül, H. (2020) · Molecular and translational medicine · doi:10.1007/978-3-030-49476-6_14
da Paixão, V. F. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2019.tde-09032020-085211 · Cited by 1
Pancreatic Cancer Immuno-oncology in the Era of Precision Medicine
Hegde, S. (2020) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-020-01192-6
López, C. A. P. (2020) · Revista Colombiana de Cancerología · doi:10.35509/01239015.713
[Global research hotspots on oncology-bibliometric analysis based on the ESI hot papers].
Han, X., Li, X., Gong, X., Li, B., Bai, B., Zhang, L., Pu, J. Y., Li, Y., & Zhang, M. (2020) · PubMed · doi:10.7507/1001-5515.202009083 · Cited by 1
MOLECULAR LANDSCAPE OF OLD AGE MELANOMA BY SURVIVAL AND IMMUNOTHERAPY RESPONSEPreprint
Smith, S. P., Nagore, E., Budden, T., Kumar, R., Marais, R., Gaudy‐Marqueste, C., & Virós, A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.27.428444
Immuntherapie mit Antikörpern: Tumorentwicklung, Immunabwehr und therapeutische Antikörper
Böldicke, T. W. (2021) · Der Onkologe · doi:10.1007/s00761-020-00895-3
A Macro-scale Comparison Algorithm for Analysis of TCR Repertoire CompletenessPreprint
Esponda, F., Šulc, P., Blattman, J. N., & Forrest, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.07.434284
Ahmed, A., Charoentong, P., Klotz, R., Köhler, S., Suarez‐Carmona, M., Valous, N. A., Ferber, D., Heikenwälder, M. F., Giese, N. A., Hackert, T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.13.435100
Jiang, P., Bao, T., Zhi, J., & Bu, S. (2021) · Journal of Biosciences · doi:10.1007/s12038-021-00189-9
Perspective on the Immunotherapy of Pancreatic Cancer
Keenan, B. P., & Tempero, M. A. (2021) · Cancer immunotherapy · doi:10.1007/13905_2021_9
Biomarkers: Is Tumor Mutational Burden the New Prognostic Grail?
Vokes, N. I., & Awad, M. M. (2021) · Current cancer research · doi:10.1007/978-3-030-74028-3_2
Biomarkers for Immunotherapy in Gastrointestinal Cancers
Palle, J., Taïeb, J., & Zaanan, A. (2021) · Cancer immunotherapy · doi:10.1007/13905_2021_10
824 High quality neoantigens are immunoedited in long-term pancreatic cancer survivors
Sethna, Z. M., Łuksza, M., Rojas, L. A., Soares, K. C., Leung, J., Lihm, J., Hoyos, D., Dobrin, A., Kappagantula, R. L., Makohon-Moore, A. P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-sitc2021.824
Self-citationProgress in research of tumor infiltrating lymphocytes in pancreatic cancer
Zhu, W., Hu, Z., & Zhou, Y. (2021) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v29.i21.1207
Metadata
- Authors
- Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., Senbabaoglu, Y., Wells, D. K., Cary, C. I. O., Grbovic-Huezo, O., Attiyeh, M., Medina, B., Zhang, J., Loo, J., Saglimbeni, J., Abu-Akeel, M., Zappasodi, R., Riaz, N., Smoragiewicz, M., Kelley, Z. L., Basturk, O., Gönen, M., Levine, A. J., Allen, P. J., Fearon, D. T., Merad, M., Gnjatic, S., Iacobuzio-Donahue, C. A., Wolchok, J. D., DeMatteo, R. P., Chan, T. A., Greenbaum, B. D., Merghoub, T., & Leach, S. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Swim Across America (US)
- University of Cambridge (GB)
- Cold Spring Harbor Laboratory (US)
- Corresponding author
- Balachandran, Vinod P.
- ORCID
- Balachandran, Vinod P.
- Łuksza, Marta
- Zhao, Julia N.
- Makarov, Vladimir
- Herbst, Brian
- Bhanot, Umesh
- Wells, Daniel K.
- Grbovic-Huezo, Olivera
- Attiyeh, Marc
- Medina, Benjamin
- Zappasodi, Roberta
- Riaz, Nadeem
- Smoragiewicz, Martin
- Gönen, Mithat
- Levine, Arnold J.
- Fearon, Douglas T.
- Gnjatic, Sacha
- Wolchok, Jedd D.
- DeMatteo, Ronald P.
- Chan, Timothy A.
- Greenbaum, Benjamin D.
- Merghoub, Taha
- Leach, Steven D.
- Venue
- Nature
- Published
- 2017-11
- Volume
- 551
- Issue
- 7681
- Pages
- 512-516
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6145146
- OpenAlex
- W2767699537
- Cited by
- 1,191
- References
- 28
- Citations by year
- 2026: 89 · 2025: 114 · 2024: 119 · 2023: 178 · 2022: 169 · 2021: 153 · 2020: 135 · 2019: 132 · 2018: 94 · 2017: 6
- FWCI
- 44.60
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (23526, 17263, 15678)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Agence Nationale de la Recherche (ANR-18-CE14-0005)
- National Institutes of Health
- National Cancer Institute (P01CA087497, P30-CA-08748, R01CA190400, P30CA008748, T32CA009501, K12CA184746)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097087)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pancreatic ductal adenocarcinoma, long-term survival, neoantigens, CA125, CD8+ T cells, T cell immunity, immunogenicity, mutational burden, immune evasion
- MeSH terms
- Cancer Survivors, Exome Sequencing, Adenocarcinoma, Antigens, Neoplasm, Bacterial Proteins, Computer Simulation, Cross Reactions, Humans, Immunotherapy, Membrane Proteins, Pancreatic Neoplasms, Prognosis, T-Lymphocytes, Cytotoxic, Survival Analysis, CA-125 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.